Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 20/20 | 0.69 |
| ▸ | SLC6A2 | P23975 | 11/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22367230 | 0.91 | CACNA2D1 (0.74) | CACNA2D1SLC6A2 | |
| SCHEMBL22367226 | 0.91 | CACNA2D1 (0.74) | CACNA2D1SLC6A2 | |
| SCHEMBL19553257 | 0.87 | CACNA2D1 (0.71) | CACNA2D1SLC6A2 | |
| SCHEMBL20999998 | 0.86 | CACNA2D1 (0.62) | CACNA2D1SLC6A2 | |
| SCHEMBL19564704 | 0.86 | CACNA2D1 (0.72) | CACNA2D1SLC6A2 | |
| SCHEMBL19564626 | 0.85 | CACNA2D1 (0.72) | CACNA2D1SLC6A2 | |
| SCHEMBL21000049 | 0.84 | CACNA2D1 (0.73) | CACNA2D1SLC6A2 | |
| SCHEMBL19564635 | 0.84 | CACNA2D1 (0.73) | CACNA2D1SLC6A2 | |
| SCHEMBL19553291 | 0.84 | CACNA2D1 (0.73) | CACNA2D1SLC6A2 | |
| SCHEMBL19564697 | 0.83 | CACNA2D1 (0.74) | CACNA2D1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11401270-B2 | Alcoxyamino derivatives for treating pain and pain related conditions | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2022-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11401270-B2 | Alcoxyamino derivatives for treating pain and pain related conditions | CACNA1B, CACNA1G, CACNA2D2 | CACNA2D1 9/4885SLC6A2 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.